These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 36574647)

  • 1. PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects,
    Zhao X; Lin Y; Liou B; Fu W; Jian J; Fannie V; Zhang W; Setchell KDR; Grabowski GA; Sun Y; Liu CJ
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2210442120. PubMed ID: 36574647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease.
    Lin Y; Zhao X; Liou B; Fannin V; Zhang W; Setchell KDR; Wang X; Pan D; Grabowski GA; Liu CJ; Sun Y
    Hum Mol Genet; 2024 Oct; 33(20):1771-1788. PubMed ID: 39101473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease.
    Liu Y; Zhao X; Jian J; Hasan S; Liu C
    Biosci Trends; 2023 May; 17(2):126-135. PubMed ID: 36889696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Progranulin and Gaucher Disease.
    Jian J; Zhao S; Tian QY; Liu H; Zhao Y; Chen WC; Grunig G; Torres PA; Wang BC; Zeng B; Pastores G; Tang W; Sun Y; Grabowski GA; Kong MX; Wang G; Chen Y; Liang F; Overkleeft HS; Saunders-Pullman R; Chan GL; Liu CJ
    EBioMedicine; 2016 Sep; 11():127-137. PubMed ID: 27515686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease.
    Jian J; Tian QY; Hettinghouse A; Zhao S; Liu H; Wei J; Grunig G; Zhang W; Setchell KDR; Sun Y; Overkleeft HS; Chan GL; Liu CJ
    EBioMedicine; 2016 Nov; 13():212-224. PubMed ID: 27789271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.
    Kinghorn KJ; Grönke S; Castillo-Quan JI; Woodling NS; Li L; Sirka E; Gegg M; Mills K; Hardy J; Bjedov I; Partridge L
    J Neurosci; 2016 Nov; 36(46):11654-11670. PubMed ID: 27852774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
    Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
    J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
    Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mini review - The role of Glucocerebrosidase and Progranulin as possible targets in the treatment of Parkinson's disease.
    Rodrigues PS; Kale PP
    Rev Neurol (Paris); 2021 Nov; 177(9):1082-1089. PubMed ID: 34175090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice.
    Gregorio I; Russo L; Torretta E; Barbacini P; Contarini G; Pacinelli G; Bizzotto D; Moriggi M; Braghetta P; Papaleo F; Gelfi C; Moro E; Cescon M
    Mol Neurodegener; 2024 Mar; 19(1):22. PubMed ID: 38454456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.
    Sanyal A; DeAndrade MP; Novis HS; Lin S; Chang J; Lengacher N; Tomlinson JJ; Tansey MG; LaVoie MJ
    Mov Disord; 2020 May; 35(5):760-773. PubMed ID: 32034799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
    Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
    Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease.
    Jackson KL; Viel C; Clarke J; Bu J; Chan M; Wang B; Shihabuddin LS; Sardi SP
    Neurobiol Dis; 2019 Oct; 130():104513. PubMed ID: 31233883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease.
    Marano M; Zizzo C; Malaguti MC; Bacchin R; Cavallieri F; De Micco R; Spagnolo F; Bentivoglio AR; Schirinzi T; Bovenzi R; Ramat S; Erro R; Sorrentino C; Sucapane P; Pilotto A; Lupini A; Magliozzi A; Di Vico I; Carecchio M; Bonato G; Cilia R; Colucci F; Tamma F; Caputo E; Mostile G; Arabia G; Modugno N; Zibetti M; Ceravolo MG; Tambasco N; Cossu G; Valzania F; Manganotti P; Di Lazzaro V; Zappia M; Fabbrini G; Tinazzi M; Tessitore A; Duro G; Di Fonzo A
    Parkinsonism Relat Disord; 2024 Jul; 124():107023. PubMed ID: 38843618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.